Effect of Aclidinium Bromide on Cardiovascular Events and COPD Exacerbations in High-Risk Patients

This randomized clinical trial compares the effects of the long-acting muscarinic antagonist aclidinium bromide vs placebo on major adverse cardiovascular events and chronic obstructive pulmonary disease (COPD) exacerbations in patients with COPD and increased cardiovascular risk.
Source: JAMA - Category: General Medicine Source Type: research